Fred Cohen, M.D., D.Phil., Partner and Managing Director
Prior to joining TPG Biotechnology in 2001, Dr. Cohen was a Professor of medicine, cellular and molecular pharmacology, biochemistry and biophysics and pharmaceutical chemistry at UCSF. In this context, he was Chief of the Division of Endocrinology and Metabolism and directed an active research program in the areas of prion biology, structure based drug design, bioinformatics and heteropolymer chemistry. Dr. Cohen is a Fellow of the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences, American College of Physicians, a member of the American Society for Clinical Investigation and the Association of American Physicians, and the recipient of several awards and honors including the Burroughs-Wellcome New Initiatives in Malaria Award, the LVMH Science Pour L’Art Prize (shared with Stanley Prusiner), a Searle Scholars Award and Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation. He graduated magna cum laude from Yale University in 1978 and received his D.Phil from Oxford University as a Rhodes Scholar in 1980, his M.D. from Stanford Medical School as an American Cancer Society Postdoctoral Fellow in 1984 and his internal medicine and endocrinology training at UCSF. He joined TPG in 2001 to initiate TPG’s venture efforts in biotechnology and life sciences. He currently serves on the board of directors of: Acumen, Inc.; BioCryst, Inc. (Nasdaq: BCRX); CareDx, Inc. (Nasdaq: CDNA); Five Prime Therapeutics, Inc. (Nasdaq: FPRX); Genomic Health, Inc. (Nasdaq: GHDX); Quintiles Transnational Corporation (NYSE: Q); Rapid Micro Biosystems Inc.; Roka Bioscience, Inc. (Nasdaq: ROKA); Tandem Inc. (Nasdaq: TNDM); and Veracyte, Inc. (Nasdaq: VCYT).
Geoff Duyk, M.D., Ph.D., Partner and Managing Director
Prior to joining TPG Biotechnology in 2004, Dr. Duyk served on the board of directors and was President of Research & Development at Exelixis, Inc., where he led a group of more than 550 people focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, Inc., he was one of the founding scientific staff at Millennium Pharmaceuticals, Inc. As Vice President of Genomics at Millennium Pharmaceuticals, Inc., Dr. Duyk was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to this, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. While at Harvard Medical School, Dr. Duyk was a Co-Principal Investigator in the NIH funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project, and has been elected to the board of directors of the American Society of Human Genetics. Dr. Duyk graduated from Wesleyan University in 1980 with a B.A. in Biology and was elected to Phi Beta Kappa. He holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at UCSF. While at UCSF, he was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Aerie Pharmaceuticals, Inc. (Nasdaq: AERI); Amyris (Nasdaq: AMRS); Beta Renewables, Inc.; DNAnexus, Inc.; Elevance Renewable Sciences, Inc.; EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS); Galleon Pharmaceuticals, Inc.; Genomatica, Inc.; Karos Pharmaceuticals, Inc.; and is a board observer at Alphabet Energy, Inc. and Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE).
Eran Nadav, Ph.D., Partner and Managing Director
Dr. Nadav joined TPG Biotech in 2007 to invest in global pharmaceuticals and biotechnology. He invests in a broad range of early to late stage companies and products, including innovative therapies and high value generics.
Prior to TPG, Dr. Nadav served as Business Development Director at Eisai, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this he worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies and biopharmaceuticals. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a Ph.D. in biochemistry, M.Sc. magna cum laude, B.Sc. magna cum laude, and MBA - all from Tel Aviv University.
Dr. Nadav currently serves as Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE), Chairman of the Board of Trevi Therapeutics, and a board member at NovaSom. His past investments and board roles include JCR Pharmaceuticals (TSE: 4552), MacroGenics (Nasdaq: MGNX), and Mayanot Eden.
Heather Preston, M.D., Partner and Managing Director
Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.
Dr. Preston co-founded Virobay Inc., a biotechnology company which is seeking to develop new therapies for the treatment of pain and auto-immune diseases. Dr. Preston currently serves on the board of directors of Albireo, Inc.; Alder BioPharmaceuticals (Nasdaq: ALDR); Otonomy, Inc. (Nasdaq: OTIC); and Virobay, Inc. She previously served on the boards of Aptalis Pharma (acquired by Forest Labs in February 2014), Conventus, Vibrynt, VLST and Elevation Pharmaceuticals (acquired by Sunovion in September 2012) and is responsible for overseeing TPG Biotech’s investment in Par Pharmaceuticals.
Mark Gudiksen, Ph.D., Principal
Dr. Gudiksen joined TPG Biotechnology in 2008, with a focus on both healthcare and industrial biotechnology. Prior to joining TPG Biotechnology, Dr. Gudiksen was at McKinsey & Company where he worked on a broad spectrum of strategic topics and M&A opportunities. Prior to this, Dr. Gudiksen received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford. His doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal. Dr. Gudiksen currently serves on the boards of directors of Alphabet Energy, Inc.; Auxogyn, Inc.; ChemEOR Inc.; and Nodality, Inc., and is a board observer at DNAnexus, Inc.
Cayce Denton, Vice President
Prior to joining TPG Biotechnology in 2010, Ms. Denton managed finance for the Nutropin and Lytics franchises at Genentech, Inc., where she also participated in a CFO Rotation Program consisting of time in R&D Finance, Financial Planning and Analysis, Audit and Treasury. Prior to Genentech, Inc., she was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, Inc. Prior to Novartis, Ms. Denton worked in biotech venture capital at Atlas Venture and was an investment banker with Credit Suisse First Boston’s Technology Group, in Boston. Ms. Denton has an MBA from the Wharton School of the University of Pennsylvania, where she was awarded the F. H. Shields Fellowship and co-founded the Biotech Investment Group, and a B.S. from M.I.T. in Biology. Ms. Denton is a board member of Karos Pharmaceuticals, Inc., PatientSafe Solutions, Inc., and Trevi Therapeutics, Inc.; and a board observer of Acumen, Inc.
Peter Bojo, Analyst
Prior to joining TPG Biotechnology in 2014, Mr. Bojo worked in management consulting at Oliver Wyman for 3 years with projects including strategy and M&A engagements within healthcare and financial services. Prior to Oliver Wyman, he worked in R&D at a medical device startup. Mr. Bojo has a Master’s and a B.S. from M.I.T. in Bioengineering, has co-authored several papers, and is a member of Tau Beta Pi and Phi Beta Kappa honor societies.